Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024 By: DiaMedica Therapeutics Inc. via Business Wire May 02, 2024 at 08:55 AM EDT DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its first quarter 2024 financial results will be released after the markets close on Wednesday, May 8th. DiaMedica will host a live conference call on Thursday, May 9th at 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: Thursday, May 9, 2023 Time: 7:00 AM CT / 8:00 AM ET Web access: https://app.webinar.net/jDdlnVm9Ewq Dial In: (646) 357-8785 Conference ID: 07657 Interested parties may access the conference call by dialing in or listening to the simultaneous webcast. Listeners should log on to the website or dial in 15 minutes prior to the call. The webcast will remain available for playback on our website, under investor relations - events and presentations, following the earnings call and for 12 months thereafter. A telephonic replay of the conference call will be available until May 16, 2024, by dialing (888) 660-6345 (US Toll Free) and entering the replay passcode: 07657#. About DiaMedica Therapeutics Inc. DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. DiaMedica’s lead candidate DM199 (rinvecalinase alfa) is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke and other vascular diseases. For more information visit the Company’s website at www.diamedica.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20240502797716/en/Contacts Scott Kellen Chief Financial Officer Phone: (763) 496-5118 skellen@diamedica.com Paul Papi Corporate Communications Phone: 617-899-5941 ppapi@diamedica.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024 By: DiaMedica Therapeutics Inc. via Business Wire May 02, 2024 at 08:55 AM EDT DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its first quarter 2024 financial results will be released after the markets close on Wednesday, May 8th. DiaMedica will host a live conference call on Thursday, May 9th at 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: Thursday, May 9, 2023 Time: 7:00 AM CT / 8:00 AM ET Web access: https://app.webinar.net/jDdlnVm9Ewq Dial In: (646) 357-8785 Conference ID: 07657 Interested parties may access the conference call by dialing in or listening to the simultaneous webcast. Listeners should log on to the website or dial in 15 minutes prior to the call. The webcast will remain available for playback on our website, under investor relations - events and presentations, following the earnings call and for 12 months thereafter. A telephonic replay of the conference call will be available until May 16, 2024, by dialing (888) 660-6345 (US Toll Free) and entering the replay passcode: 07657#. About DiaMedica Therapeutics Inc. DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. DiaMedica’s lead candidate DM199 (rinvecalinase alfa) is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke and other vascular diseases. For more information visit the Company’s website at www.diamedica.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20240502797716/en/Contacts Scott Kellen Chief Financial Officer Phone: (763) 496-5118 skellen@diamedica.com Paul Papi Corporate Communications Phone: 617-899-5941 ppapi@diamedica.com
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its first quarter 2024 financial results will be released after the markets close on Wednesday, May 8th. DiaMedica will host a live conference call on Thursday, May 9th at 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: Thursday, May 9, 2023 Time: 7:00 AM CT / 8:00 AM ET Web access: https://app.webinar.net/jDdlnVm9Ewq Dial In: (646) 357-8785 Conference ID: 07657 Interested parties may access the conference call by dialing in or listening to the simultaneous webcast. Listeners should log on to the website or dial in 15 minutes prior to the call. The webcast will remain available for playback on our website, under investor relations - events and presentations, following the earnings call and for 12 months thereafter. A telephonic replay of the conference call will be available until May 16, 2024, by dialing (888) 660-6345 (US Toll Free) and entering the replay passcode: 07657#. About DiaMedica Therapeutics Inc. DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. DiaMedica’s lead candidate DM199 (rinvecalinase alfa) is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke and other vascular diseases. For more information visit the Company’s website at www.diamedica.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20240502797716/en/
Scott Kellen Chief Financial Officer Phone: (763) 496-5118 skellen@diamedica.com Paul Papi Corporate Communications Phone: 617-899-5941 ppapi@diamedica.com